Description: Hutchison China MediTech Limited engages in the research, development, manufacture, and sale of pharmaceuticals and health oriented consumer products primarily in the People's Republic of China. It operates through three segments: China Healthcare, Drug Research and Development, and Consumer Products. The company manufactures, distributes, and sells over-the-counter, prescription, and health supplements products under the Bai Yun Shan and Shang Yao brands; and offers drug research and development services. It also offers traditional Chinese medicine products in cardiovascular and cold/flu therapeutic areas. In addition, the company develops clinical drug candidates, including HMPL-004 that is in Phase III clinical trials for ulcerative colitis and Crohn's disease; Fruquintinib, which is in Phase III clinical trial for the treatment of colorectal, non-small cell lung, and gastric cancer; and Sulfatinib, a Phase 1b clinical trial product for neuroendocrine tumours, as well as Epitinib for treating non-small cell lung cancer. Further, it offers Theliatinib, a Phase I clinical trial product for the treatment of solid tumours; AZD6094 that is in Phase 1b clinical trial for treating non-small cell lung and gastric cancer; HMPL-523 and HMPL-689, which are preclinical stage products for the treatment of hematological cancers; and HMPL-453 that is in preclinical stage for the treatment of solid tumours. The company also offers organic and natural food, beverage, baby, and beauty care products; and distributes organic and natural products. Hutchison China MediTech Limited has strategic collaborations with multinational pharmaceutical and healthcare companies, including AstraZeneca AB (Publ); Eli Lilly and Company; Janssen Pharmaceuticals, Inc.; and Nestlé Health Science SA. The company was founded in 2000 and is based in Hong Kong, Hong Kong. Hutchison China MediTech Limited operates as a subsidiary of Hutchison Healthcare Holdings Limited.
Home Page: www.hutch-med.com
HCM Technical Analysis
Cheung Kong Center
Central,
Hong Kong
Phone:
852 2128 1188
Officers
| Name | Title |
|---|---|
| Mr. Chi Keung To ACGI, B.Sc., BSc, M.B.A., MBA | Exec. Chairman |
| Dr. Weiguo Su B.Sc., Ph.D. | CEO, Chief Scientific Officer & Exec. Director |
| Mr. Chig Fung Cheng BEc, CA | CFO & Exec. Director |
| Ms. Edith Shih C.S., CGP, FCS, M.A., P.E., BSE, EdM, Solicito | Company Sec. & Non-Exec. Director |
| Dr. Karen Jane Atkin | Exec. VP & COO |
| Mr. Kin Hung Lee M.B.A. | Sr. VP of Corp. Fin. & Devel. |
| Mr. Charles George Rupert Nixon | Group Gen. Counsel |
| Ms. Selina Zhang | Sr. VP of Global HR |
| Dr. Qingmei Wang Ph.D. | Sr. VP of Bus. Devel. & Strategic Alliances |
| Mr. Hong Chen | Sr. VP & Chief Commercial Officer- China |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Pharmaceuticals |
| GIC Sub-Industry: | Pharmaceuticals |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.0277 |
| Price-to-Sales TTM: | 5.9678 |
| IPO Date: | 2016-03-17 |
| Fiscal Year End: | December |
| Full Time Employees: | 2110 |